Alzheimer’s Disease: Solanezumab Drug Trial Flops (BBC News / Alzheimer’s and Dementia)

Summary

The phase 3 EXPEDITION3 trial has been abandoned, as Solanezumab failed to slow cognitive decline in tests on around 2,000 patients with Alzheimer’s Disease.

Several other amyloid-clearance drugs are going through trials apparently.

Full Text Link

Reference

Walsh, F. (2016). Hopes for new Alzheimer’s drug dashed. London: BBC Health News, November 23rd 2016.

Earlier hopes (background):

Full Text Link

Reference

Siemers, ER. Sundell, KL. [and] Carlson, C. [et al] (2016). Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimer’s and Dementia. 2016 Feb;12(2):110-20.

Advertisements

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in BBC News, For Researchers (mostly), In the News, International, Pharmacological Treatments, Quick Insights, Universal Interest and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s